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ABSTRACT 
Objective: Bergenia ciliata (family-Saxifragaceae) is a well-known herb for kidney stone. The main objective of the study was the identification of 
flavonoids along with ADME profile. Another supportive objective was to check inhibition of enzymes which perform active role in oxalate synthesis.  
Methods: The hydromethanolic extract was fractionated by liquid-liquid extraction to obtain ethyl acetate and ethyl ether fractions. The chemical 
structures of the purified compounds were identified by gas chromatography-mass spectrometry. 
Results: A total of 12 volatile chemical compounds belonging to hydrocarbons, esters, alcohols, fatty acids, ketones, etc. were identified and 
characterized in ethyl acetate fraction through GC-MS analysis Fractions enriched in flavonoids showed glycolate oxidase and lactate 
dehydrogenase enzyme inhibition with IC50 value (µg/ml) 65.76 and 69.84 respectively. The kinetic behaviour of the extracts that inhibit the 
Glycolate oxidase and Lactate dehydrogenase activity was determined by the Lineweaver-Burk plot. The mode of inhibition of the studied plant 
extract was type of a non-competitive inhibition. ADMET screening of compounds successfully passed all the parameters of screening. 
Conclusion: On the basis of the results, it was found that Bergenia ciliata (rhizome) may serve as a novel and rich source of therapeutic compounds 
and it can be further explored for urolithiasis treatment purposes. 
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INTRODUCTION 
Flavonols are a class of flavonoids that have the 3-hydroxyflavone 
backbone (IUPAC name: 3-hydroxy-2-phenylchromen-4-one). 
Flavonoids help regulate cellular activity and fight off free radicals 
that cause oxidative stress on your body. In simpler terms, they help 
your body function more efficiently while protecting it against 
everyday toxins and stressors. Flavonoids are also powerful 
antioxidant agents. Flavonoid-rich foods, based on their surprising 
health effects, are well described as superfoods. These include all 
plant-origin foods, mainly tea, fruit, vegetables, grains, legumes, 
nuts, and wine [1]. Flavonoids are important for human health 
because of their antioxidant, antibacterial, antiviral, antihepatotoxic, 
antiosteoporotic, antiulcer, immunomodulatory, antiproliferative 
and apoptotic activity and anti-inflammatory activities and because 
they act as free radical scavengers as they are potential reducing 
agents that protect from oxidative damage [2-10]. Bergenia ciliata 
Sternb. (family-Saxifragaceae), a high-value plant of the Sikkim 
Himalaya has been investigated for antioxidant, antiurolithiac 
activity and bioactive compounds. However, scientific exploration of 
B. ciliata for phytochemicals and pharmacological properties is in 
infancy. With this view, the present study was undertaken to 
investigate B. ciliata rhizome ethanolic extract for antiurolithiac 
activity and bioactive compounds. Glycolate oxidase (GOX, EC 
1.1.3.15) the key enzyme involved in oxalate synthesis. It was first 
associated with the disease primary hyperoxaluria type1 (PH1). The 
inhibition of GOX activity is a suitable therapeutic strategy for 
decreasing endogenous oxalate synthesis. The oxidation of Glycolate 
to glyoxylate is catalyzed by Glycolate oxidase [11] and the 
reduction of glyoxylate to Glycolate by lactate dehydrogenase (LDH) 
(EC 1.1.1.27) [12-14]. In normal pathway, alanine glyoxylate 
aminotransferase (AGT) converts glyoxylate to glycine and so 
prevents the conversion of glyoxylate to oxalate which further form 
complex with calcium to lead into the formation of calcium oxalate 
stones (fig. 1.) [15]. In the case of AGT deficiency, glyoxylate gets 
directly converted to oxalate by enzymes GOX and LDH. Hence their 
inhibition proves potential in the management of urolithiasis [16]. 
GC-MS analysis can identify pure compounds present at less than 1 
gm [17]. Simple, cost-effective spectroscopic (UV-Vis, FTIR, GC-MS) 
methods together or separate can be used for detecting photo 
components in this sense as well as conventional methods [18-20]. 
So far reports on the systematic evaluation and scientific 
investigation of Bergenia ciliata or their phytoconstituents as 
glycolate oxidase and lactate dehydrogenase inhibitors are scare. 
The mode of interaction of extracted flavonoids (inhibitor) with 
enzyme, including identifying constituent compounds using GCMS, 
determining IC50 values using inhibition kinetics analysis and 
determining inhibitory patterns using Lineweaver-Burk plots and 




Fig. 1: Pathway associated with oxalate synthesis 
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MATERIALS AND METHODS 
Flavonoid extraction from Bergenia ciliata (rhizome) 
Bergenia ciliata (rhizome) was procured from Yogesh pharma Pvt. 
Ltd., Nanded (MS), India. The plant material was washed thoroughly 
with water to remove dust and dried under the shade at room 
temperature for 5 d. The dried parts were ground using blender to 
obtain the course powder and kept in an air-tight container till 
further use. Extraction of flavonoids was done as per method 
reported by Subramnian S and Nagarjan S [21]. Hundred grams of 
finely powdered sample were soxhlet extracted with 80% hot 
methanol (500 ml) on a water bath for 24 h and filtered. The filtrate 
obtained was re-extracted successively with petroleum ether 
(fraction I), ethyl ether (fraction II), and ethyl acetate (fraction III) 
using separating funnel. Fraction of petroleum ether was discarded 
due to being rich in fatty substances. The fractions of (ethyl ether-
fraction II) and (ethyl acetate-fraction III) were further analysed for 
free and bound flavonoids, respectively. Ethyl acetate fraction of the 
sample was refluxed for the hydrolysis using 7% H2SO4 for 2 h (for 
removal of bounded sugars) and again filtrate was extracted in 
separating funnel with ethyl acetate. Ethyl acetate extract thus 
obtained was washed with distilled water to neutrality. Ethyl ether 
(free flavonoids) and ethyl acetate fractions (bound flavonoids) 
were dried in rota vapour and weighed. 
Gas chromatography-mass spectrometry analysis 
The GC-MS analysis of the ethanolic extract was carried out using a 
Agilent 7890 A gas chromatogram equipped and coupled to a mass 
detector 5975 MSD spectrometer with DB 5 MS and 30m × 0.25 µm 
DF of capillary column. Ultra-high purity helium (99.99%) was used 
as carrier gas at a constant flow rate of 1.0 ml/min. The injection, 
transfer line and ion source temperatures were at all 290 °C. The 
ionizing energy was 70 eV. Electron multiplier voltage was obtained 
from autotune. The oven temperature was programmed from 60 °C 
(hold for 2 min) to 320 °C at a rate of 3 °C/min. The crude sample 
was diluted with an appropriate solvent (1/10, v/v) and filtered. The 
particle-free diluted crude extracts (1 μL) were taken in a syringe 
and injected into injector with a split ratio 30:1. All data were 
obtained by collecting the full-scan mass spectra within the scan 
range 30-600 amu. The percentage composition of the crude extract 
constituents was expressed as a percentage by peak area. The 
identification and characterization of chemical compounds in 
ethanolic crude extract were based on GC retention time. AMDIS and 
NIST Version-Year 2011 was used MS data library and comparing 
the spectrum obtained through GC-MS compounds present in the 
plant’s sample was identified. 
Glycolate oxidase enzyme inhibition assay  
Glycolate oxidase enzyme inhibition activity was performed in 
cuvette with a 1-cm light path using a UV-spectrophotometer. Each 
assay contained 200μM potassium phosphate (pH 7.0), 1 mg of 
bovine serum albumin, 3μM EDTA, 0.1μM DCIP, enzyme and water 
to a volume of 3 ml and a solution of test plant extracts in DMSO was 
incubated at room temperature for 15 min. The reaction was started 
by the addition of 2μM Sodium glycolate was then followed by 
measure of the decrease in absorbance at 600 nm. The inhibitory 
activity of each test compound was indicated by their IC50 values 
calculated using a linear regression curve. The percent inhibition of 
enzyme activity was calculated using standard formula [22].  
 
Where control represents reaction mixture as described above 
excluding test compounds instead contain DMSO only whereas 
sample represents reaction mixture same as described in method. 
Lactate dehydrogenase enzyme inhibition assay  
Lactate dehydrogenase activity was assayed at pH 7.4 by measuring 
the decrease in absorbance at 340 nm associated with NADH 
oxidation. Assay mixture contained 0.3 mmol NADH, 2.0 mmol 
pyruvate and 100 μL enzyme in volume of 3.0 ml. The reaction was 
started by the addition of enzyme. Lactate dehydrogenase inhibitory 
activity of test plant extracts was monitored spectrophotometrically 
following the absorbance at 340 nm under aerobic condition. The 
reaction mixture containing 0.3 mmol NADH, 100 μL enzymes in 
volume of 3.0 ml and a solution of test plant extracts in DMSO was 
incubated at room temperature for 15 min. The reaction was started 
by addition of 2 mmol pyruvate and l-lactate formation was then 
followed by measure of decrease in absorbance at 340 nm. The 
inhibitory activity of each test compound was indicated by their IC50 
values calculated using linear regression curve. The percent inhibition 
of enzyme activity was calculated using standard formula [22].  
 
Where control represents reaction mixture as described above 
excluding test compounds instead contain DMSO only whereas 
sample represents reaction mixture same as described in method. 
ADMET predictions 
ADMET (Absorption, Distribution, Metabolism, Excretion and 
Toxicity) analyses constitute the pharmacokinetics of a drug 
molecule [23]. In this study, prediction and significant descriptors of 
drug-likeness such as mutagenicity, toxicological dosage level and 
pharmacologically relevant properties of the compounds were 
predicted using Swissadme (http://www.swissadme.ch) and 
admetSAR (lmmd.ecust.edu.cn: 8000) servers. 
RESULTS AND DISCUSSION 
Flavonoid extraction from Bergenia ciliata (rhizome) 
The ethyl acetate fraction of Bergenia ciliata (rhizome) showed 
many peaks in the chromatogram (fig. 2a), however, only twelve 
compounds could be identified and characterized (fig. 2b). Plants 
contain so many phytoconstituents, many of which are biologically 
active compounds and are responsible for pharmacological activities 
[24]. The bioactive secondary metabolites have been shown to 
reduce the risk and progression of diseases such as cancer, renal 
disorders, etc., through various biological mechanisms. A total of 12 
volatile chemical compounds belonging to hydrocarbons, esters, 
alcohols, fatty acids, ketones, etc. were identified and characterized 
in ethyl acetate fraction through GC-MS analysis (table 1).  
Glycolate oxidase and lactate dehydrogenase inhibition and 
mode of inhibition Lineweaver–Burk plots  
The experimental evidence indicates that ethyl acetate fraction of 
Bergenia ciliata showed a good activity profile for inhibition of 
glycolate oxidase and lactate dehydrogenase as indicated by IC50 
(μM) (fig. 3; table 2). To determine the mode of inhibition by active 
compounds from the plants, Lineweaver–Burk plot analysis was 
performed [25]. This kinetics study was carried out in the absence 
and presence of active compounds with varying concentrations of 
substrate. The initial velocity was expressed as the absorbance 
decrease at 340 nm for lactate dehydrogenase and 600 nm for 
glycolate oxidase per 10 s in the assay. In case of glycolate oxidase 
and lactate dehydrogenase inhibition, B. ciliata (ethyl acetate 
fraction) were found to be non-competitive inhibitors as Km values 
were constant while Vmax consequently decreased with increased 
inhibitor concentration. These finding suggest that inhibition of 
glycolate oxidase and lactate dehydrogenase activity, leading to 
retardation of oxalate synthesis, is one of the mechanism through 
which the plant tested in this study could be exhibiting their 
antiurolithiac effect. Modulation of glycolate oxidase and lactate 
dehydrogenase activity by compounds in these extracts would thus 
eventually lead to a lowering of oxalate content. Presence of 
glycolate oxidase and lactate dehydrogenase inhibitor blocks the 
normal pathway of conversion of glyoxylate to oxalate which further 
form a complex with calcium to lead into the formation of calcium 
oxalate stones. Thus, oxalate synthesis can be blocked in 
hyperoxaluria conditions with glycolate oxidase and lactate 
dehydrogenase inhibitors. This glycolate oxidase and lactate 
dehydrogenase inhibition could occur in a concentration-dependent 
or independent manner depending upon the bioactive compounds. 
Inhibition of glycolate oxidase and lactate dehydrogenase may occur 
due to these phytoconstituents. This is the first report as per 
author’s knowledge. 
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Fig. 2a: Total ion chromatogram (GC-MS) of Bergenia ciliata (rhizome) (ethyl acetate fraction) 
 
 
[1]: 2,5-Furandione, dihydro-3-methylene-[2]: α-D-Glucopyranoside,O-α-D-glucopyranosyl-(fwdarw 3)-β-D-fructofuranosyl, [3]: Fumaric acid, [4]: 
2-decenoic acid, [5]: 1,2,3-Benzenetriol, [6]: Benzoic acid, 3-hydroxy- 
 
 
[7]: 1,2,3,5-Cyclohexanetetrol, (1α,2β,3α,5β), [8]: Nonadecane, [9]: Benzoic acid, 4-hydroxy-3,5-dimethoxy-, [10]: 8-pentadecanone, [11]: Docosene, 
[12]: 2,5- Furandione,3-methyl- 
Fig. 2b: Ion chromatograms (GC-MS) of identified compounds from Bergenia ciliata (rhizome) (ethyl acetate fraction) 
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Table 1: Bioactivity of phytocomponents identified in the ethyl acetate fraction of Bergenia ciliata 
Bergenia ciliata (Ethyl acetate fraction) 
Name of the compound Biological Activity** 
Fumaric acid Acidifier, Acidulant, Arachidonic acid-inhibitor, Increase aromatic 
amino acid Decarboxylase activity, Inhibit production of uric acid, 
Urinary-Acidulant, Urine-acidifier.  
α-D-Glucopyranoside, O-α-D-glucopyranosyl-(fwdarw 3)-β-D-
fructofuranosyl 
Aldehyde-oxidase-inhibitor, Anticancer, Antidote, Antiretinitic, 
Antitumor, Catechol-O-Methyl-Transferase-Inhibitor, Increase 
Osteocalcin, Inhibit Production of Tumor Necrosis Factor, Inhibit 
production of uric acid, Lower oxalate, Ionic Channel Opener, NADH-
Oxidase Inhibitor, Nitric Oxide Synthase Inhibitor, Occuloirritant, 
Occulotensive, Odontolytic 
2-decenoic acid Acidifier, Acidulant, Arachidonic acid-inhibitor, Increased aromatic 
amino acid Decarboxylase activity, Inhibit production of uric acid, 
Urinary-Acidulant, Urine-acidifier.  
Benzoic acid, 3-hydroxy- 17-beta-hydroxysteroid dehydrogenase-inhibitor, Aryl-Hydrocarbon-
Hydroxylase-Inhibitor, Testosterone-Hydroxylase-Inducer, Acidifier, 
Acidulant, Arachidonic acid-inhibitor, Increase aromatic amino acid 
Decarboxylase activity, Inhibit production of uric acid, Urinary-
Acidulant, Urine-acidifier. 
Benzoic acid, 4-hydroxy-3,5-dimethoxy- Acidifier, Acidulant, Arachidonic acid-inhibitor, Increased aromatic 
amino acid Decarboxylase activity, Inhibit production of uric acid, 






(**Activity source: Dr. Duke's Phytochemical and Ethnobotanical Database) 
 
Table 2: Vmax and Km of B. ciliata (ethyl acetate extracts) for glycolate oxidase (GOX) and lactate dehydrogenase (LDH) inhibition 
Samples  Concentrations (µg/ml)  Vmax (µg/min)  Km (µg/ml)  Type of Inhibition  IC50 value (µg/ml)  
B. ciliata (gox)  10  0.025  0.86  Non-competitive  65.76  
25  0.025  0.86  
50  0.029  0.8  
75  0.0196  0.8  
100  0.0181  0.8  
B. ciliata (ldh)  10  3.33  1.75  Non-competitive  69.84  
25  1.66  1.75  
50  1.25  1.63  
75  1.25  1.63  
100  1.42  1.63  
 
 
Fig. 3: Lineweaver-Burk plot for enzyme Glycolate oxidase and Lactate dehydrogenase 
 
ADMET predictions 
The potential ADME profiles of the compounds as predicted 
using the admetSAR server, while the distribution profile of the 
compounds as obtained from the admetSAR server is shown 
in (table 11). Computational study for the prediction of the 
relevant properties influencing bioactivity of the lead 
compounds was performed. The ADME properties of the 
compounds were evaluated, and the selected properties are 
linked to metabolism and cell permeation. 
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Compound 1: 1,2,3-Benzenetriol 
 
ADMET predicted profile---Classification 
Model Result Probability 
Absorption 
Blood-Brain Barrier BBB- 0.6478 
Human Intestinal Absorption HIA+ 0.9642 
Caco-2 Permeability Caco2+ 0.7355 
P-glycoprotein Substrate Non-substrate 0.6749 
P-glycoprotein Inhibitor Non-inhibitor 0.9691 
Non-inhibitor 0.9916 
Renal Organic Cation Transporter Non-inhibitor 0.9289 
Distribution 
Subcellular localization Mitochondria 0.6807 
Metabolism 
CYP450 2C9 Substrate Non-substrate 0.8234 
CYP450 2D6 Substrate Non-substrate 0.9031 
CYP450 3A4 Substrate Non-substrate 0.7441 
CYP450 1A2 Inhibitor Non-inhibitor 0.7436 
CYP450 2C9 Inhibitor Non-inhibitor 0.8271 
CYP450 2D6 Inhibitor Non-inhibitor 0.9494 
CYP450 2C19 Inhibitor Non-inhibitor 0.9397 
CYP450 3A4 Inhibitor Non-inhibitor 0.8682 
CYP Inhibitory Promiscuity Low CYP Inhibitory Promiscuity 0.6899 
Excretion 
Toxicity 
Human Ether-a-go-go-Related Gene Inhibition Weak inhibitor 0.9526 
Non-inhibitor 0.9299 
AMES Toxicity AMES toxic 0.7459 
Carcinogens Non-carcinogens 0.8816 
Fish Toxicity High FHMT 0.6928 
Tetrahymena Pyriformis Toxicity High TPT 0.8900 
Honey Bee Toxicity High HBT 0.6927 
Biodegradation Ready biodegradable 0.6003 
Acute Oral Toxicity III 0.8089 
Carcinogenicity (Three-class) Non-required 0.5339 
ADMET predicted profile---Regression 
Model Value Unit 
Absorption 
Aqueous solubility -0.4107 LogS 





Rat Acute Toxicity 2.2344 LD50, mol/kg 
Fish Toxicity 1.1417 pLC50, mg/l 
Tetrahymena Pyriformis Toxicity 0.5649 pIGC50, ug/l 
 
Compound 2: 2-decenoic acid 
 
ADMET predicted profile---Classification 
Model Result Probability 
Absorption 
Blood-Brain Barrier BBB+ 0.9638 
Human Intestinal Absorption HIA+ 0.9908 
Caco-2 Permeability Caco2+ 0.8326 
P-glycoprotein Substrate Non-substrate 0.6523 
P-glycoprotein Inhibitor Non-inhibitor 0.9689 
Non-inhibitor 0.7699 
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Model Result Probability 
Renal Organic Cation Transporter Non-inhibitor 0.9061 
Distribution 
Subcellular localization Plasma membrane 0.6894 
Metabolism 
CYP450 2C9 Substrate Non-substrate 0.7322 
CYP450 2D6 Substrate Non-substrate 0.9059 
CYP450 3A4 Substrate Non-substrate 0.7043 
CYP450 1A2 Inhibitor Inhibitor 0.7152 
CYP450 2C9 Inhibitor Non-inhibitor 0.8948 
CYP450 2D6 Inhibitor Non-inhibitor 0.9474 
CYP450 2C19 Inhibitor Non-inhibitor 0.9459 
CYP450 3A4 Inhibitor Non-inhibitor 0.9608 
CYP Inhibitory Promiscuity Low CYP Inhibitory Promiscuity 0.8882 
Excretion 
Toxicity 
Human Ether-a-go-go-Related Gene Inhibition Weak inhibitor 0.8983 
Non-inhibitor 0.9369 
AMES Toxicity Non AMES toxic 0.9737 
Carcinogens Non-carcinogens 0.5263 
Fish Toxicity High FHMT 0.9784 
Tetrahymena Pyriformis Toxicity High TPT 0.9996 
Honey Bee Toxicity High HBT 0.7359 
Biodegradation Ready biodegradable 0.7618 
Acute Oral Toxicity III 0.8593 
Carcinogenicity (Three-class) Non-required 0.6623 
ADMET predicted profile---Regression 
Model Value Unit 
Absorption 
Aqueous solubility -3.5855 LogS 





Rat Acute Toxicity 1.9685 LD50, mol/kg 
Fish Toxicity 0.8959 pLC50, mg/l 
Tetrahymena Pyriformis Toxicity 0.7180 pIGC50, ug/l 
 
Compound 3: 8-pentadecanone 
 
ADMET predicted profile---Classification 
Model Result Probability 
Absorption 
Blood-Brain Barrier BBB+ 0.9882 
Human Intestinal Absorption HIA+ 0.9955 
Caco-2 Permeability Caco2+ 0.8766 
P-glycoprotein Substrate Non-substrate 0.6680 
P-glycoprotein Inhibitor Non-inhibitor 0.8320 
Non-inhibitor 0.7768 
Renal Organic Cation Transporter Non-inhibitor 0.8727 
Distribution 
Subcellular localization Mitochondria 0.4585 
Metabolism 
CYP450 2C9 Substrate Non-substrate 0.8589 
CYP450 2D6 Substrate Non-substrate 0.8439 
CYP450 3A4 Substrate Non-substrate 0.6531 
CYP450 1A2 Inhibitor Inhibitor 0.6890 
CYP450 2C9 Inhibitor Non-inhibitor 0.9433 
CYP450 2D6 Inhibitor Non-inhibitor 0.9502 
CYP450 2C19 Inhibitor Non-inhibitor 0.9645 
CYP450 3A4 Inhibitor Non-inhibitor 0.9815 
CYP Inhibitory Promiscuity Low CYP Inhibitory Promiscuity 0.8752 
Excretion 
Toxicity 
Human Ether-a-go-go-Related Gene Inhibition Weak inhibitor 0.8043 
Non-inhibitor 0.7659 
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Model Result Probability 
AMES Toxicity Non AMES toxic 0.9859 
Carcinogens Carcinogens 0.6310 
Fish Toxicity High FHMT 0.7423 
Tetrahymena Pyriformis Toxicity High TPT 0.8910 
Honey Bee Toxicity High HBT 0.7254 
Biodegradation Ready biodegradable 0.8731 
Acute Oral Toxicity III 0.8455 
Carcinogenicity (Three-class) Non-required 0.7622 
ADMET predicted profile---Regression 
Model Value Unit 
Absorption 
Aqueous solubility -2.2537 LogS 





Rat Acute Toxicity 1.5870 LD50, mol/kg 
Fish Toxicity 0.8094 pLC50, mg/l 
Tetrahymena Pyriformis Toxicity 0.5873 pIGC50, ug/l 
 
Compound 4: Benzoic acid, 3-hydroxy- 
 
ADMET predicted profile---Classification 
Model Result Probability 
Absorption 
Blood-Brain Barrier BBB+ 0.5320 
Human Intestinal Absorption HIA+ 0.9872 
Caco-2 Permeability Caco2+ 0.8937 
P-glycoprotein Substrate Non-substrate 0.7493 
P-glycoprotein Inhibitor Non-inhibitor 0.9890 
Non-inhibitor 0.9927 
Renal Organic Cation Transporter Non-inhibitor 0.9078 
Distribution 
Subcellular localization Mitochondria 0.9063 
Metabolism 
CYP450 2C9 Substrate Non-substrate 0.8115 
CYP450 2D6 Substrate Non-substrate 0.9377 
CYP450 3A4 Substrate Non-substrate 0.7652 
CYP450 1A2 Inhibitor Non-inhibitor 0.9752 
CYP450 2C9 Inhibitor Non-inhibitor 0.9697 
CYP450 2D6 Inhibitor Non-inhibitor 0.9827 
CYP450 2C19 Inhibitor Non-inhibitor 0.9651 
CYP450 3A4 Inhibitor Non-inhibitor 0.9493 
CYP Inhibitory Promiscuity Low CYP Inhibitory Promiscuity 0.9554 
Excretion 
Toxicity 
Human Ether-a-go-go-Related Gene Inhibition Weak inhibitor 0.9617 
Non-inhibitor 0.9771 
AMES Toxicity Non AMES toxic 0.9826 
Carcinogens Non-carcinogens 0.8226 
Fish Toxicity High FHMT 0.7616 
Tetrahymena Pyriformis Toxicity Low TPT 0.8365 
Honey Bee Toxicity High HBT 0.7797 
Biodegradation Ready biodegradable 0.8413 
Acute Oral Toxicity III 0.5472 
Carcinogenicity (Three-class) Non-required 0.6300 
ADMET predicted profile---Regression 
Model Value Unit 
Absorption 
Aqueous solubility -1.3479 LogS 
Caco-2 Permeability 1.1511 LogPapp, cm/s 
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Rat Acute Toxicity 1.3983 LD50, mol/kg 
Fish Toxicity 2.2036 pLC50, mg/l 
Tetrahymena Pyriformis Toxicity -0.8949 pIGC50, ug/l 
 
Compound 5: Benzoic acid, 4-hydroxy-3,5-dimethoxy 
 
ADMET predicted profile---Classification 
Model Result Probability 
Absorption 
Blood-Brain Barrier BBB+ 0.5861 
Human Intestinal Absorption HIA+ 0.9165 
Caco-2 Permeability Caco2+ 0.7124 
P-glycoprotein Substrate Non-substrate 0.6033 
P-glycoprotein Inhibitor Non-inhibitor 0.9199 
Non-inhibitor 0.8879 
Renal Organic Cation Transporter Non-inhibitor 0.9136 
Distribution 
Subcellular localization Mitochondria 0.8825 
Metabolism 
CYP450 2C9 Substrate Non-substrate 0.8213 
CYP450 2D6 Substrate Non-substrate 0.8899 
CYP450 3A4 Substrate Non-substrate 0.6258 
CYP450 1A2 Inhibitor Non-inhibitor 0.9052 
CYP450 2C9 Inhibitor Non-inhibitor 0.9316 
CYP450 2D6 Inhibitor Non-inhibitor 0.9445 
CYP450 2C19 Inhibitor Non-inhibitor 0.8579 
CYP450 3A4 Inhibitor Non-inhibitor 0.9538 
CYP Inhibitory Promiscuity Low CYP Inhibitory Promiscuity 0.8767 
Excretion 
Toxicity 
Human Ether-a-go-go-Related Gene Inhibition Weak inhibitor 0.9858 
Non-inhibitor 0.9664 
AMES Toxicity Non AMES toxic 0.9342 
Carcinogens Non-carcinogens 0.8809 
Fish Toxicity High FHMT 0.8272 
Tetrahymena Pyriformis Toxicity High TPT 0.9067 
Honey Bee Toxicity High HBT 0.7522 
Biodegradation Ready biodegradable 0.7199 
Acute Oral Toxicity II 0.4765 
Carcinogenicity (Three-class) Non-required 0.7159 
 
ADMET predicted profile---Regression 
Model Value Unit 
Absorption 
Aqueous solubility -2.1167 LogS 





Rat Acute Toxicity 2.5353 LD50, mol/kg 
Fish Toxicity 1.6288 pLC50, mg/l 
Tetrahymena Pyriformis Toxicity 0.4613 pIGC50, ug/l 
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Compound 6: Docosene 
 
ADMET predicted profile---Classification 
Model Result Probability 
Absorption 
Blood-Brain Barrier BBB+ 0.9763 
Human Intestinal Absorption HIA+ 0.9928 
Caco-2 Permeability Caco2+ 0.7989 
P-glycoprotein Substrate Non-substrate 0.6522 
P-glycoprotein Inhibitor Non-inhibitor 0.7775 
Non-inhibitor 0.5881 
Renal Organic Cation Transporter Non-inhibitor 0.8619 
Distribution 
Subcellular localization Lysosome 0.4578 
Metabolism 
CYP450 2C9 Substrate Non-substrate 0.8261 
CYP450 2D6 Substrate Non-substrate 0.8048 
CYP450 3A4 Substrate Non-substrate 0.7278 
CYP450 1A2 Inhibitor Inhibitor 0.5418 
CYP450 2C9 Inhibitor Non-inhibitor 0.9157 
CYP450 2D6 Inhibitor Non-inhibitor 0.9426 
CYP450 2C19 Inhibitor Non-inhibitor 0.9190 
CYP450 3A4 Inhibitor Non-inhibitor 0.9832 
CYP Inhibitory Promiscuity Low CYP Inhibitory Promiscuity 0.6838 
Excretion 
Toxicity 
Human Ether-a-go-go-Related Gene Inhibition Weak inhibitor 0.7812 
Non-inhibitor 0.8777 
AMES Toxicity Non AMES toxic 0.9904 
Carcinogens Carcinogens 0.6000 
Fish Toxicity High FHMT 0.9954 
Tetrahymena Pyriformis Toxicity High TPT 0.9981 
Honey Bee Toxicity High HBT 0.7751 
Biodegradation Ready biodegradable 0.5000 
Acute Oral Toxicity III 0.6572 
Carcinogenicity (Three-class) Non-required 0.5494 
ADMET predicted profile---Regression 
Model Value Unit 
Absorption 
Aqueous solubility -4.9876 LogS 





Rat Acute Toxicity 1.3452 LD50, mol/kg 
Fish Toxicity -1.1807 pLC50, mg/l 
Tetrahymena Pyriformis Toxicity 1.4804 pIGC50, ug/l 
 
Compound 7: fumaric acid 
 
ADMET predicted profile---Classification 
Model Result Probability 
Absorption 
Blood-Brain Barrier BBB+ 0.9017 
Human Intestinal Absorption HIA+ 0.8740 
Caco-2 Permeability Caco2- 0.6728 
P-glycoprotein Substrate Non-substrate 0.8006 
P-glycoprotein Inhibitor Non-inhibitor 0.9850 
Non-inhibitor 0.9808 
Renal Organic Cation Transporter Non-inhibitor 0.9583 
Distribution 
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Model Result Probability 
Subcellular localization Mitochondria 0.7863 
Metabolism 
CYP450 2C9 Substrate Non-substrate 0.8262 
CYP450 2D6 Substrate Non-substrate 0.9397 
CYP450 3A4 Substrate Non-substrate 0.8039 
CYP450 1A2 Inhibitor Non-inhibitor 0.9659 
CYP450 2C9 Inhibitor Non-inhibitor 0.9490 
CYP450 2D6 Inhibitor Non-inhibitor 0.9606 
CYP450 2C19 Inhibitor Non-inhibitor 0.9773 
CYP450 3A4 Inhibitor Non-inhibitor 0.9554 
CYP Inhibitory Promiscuity Low CYP Inhibitory Promiscuity 0.9899 
Excretion 
Toxicity 
Human Ether-a-go-go-Related Gene Inhibition Weak inhibitor 0.9836 
Non-inhibitor 0.9891 
AMES Toxicity Non AMES toxic 0.9132 
Carcinogens Non-carcinogens 0.5130 
Fish Toxicity High FHMT 0.8398 
Tetrahymena Pyriformis Toxicity Low TPT 0.9808 
Honey Bee Toxicity High HBT 0.7308 
Biodegradation Ready biodegradable 0.7561 
Acute Oral Toxicity III 0.7762 
Carcinogenicity (Three-class) Non-required 0.7191 
ADMET predicted profile---Regression 
Model Value Unit 
Absorption 
Aqueous solubility -0.3321 LogS 





Rat Acute Toxicity 1.6871 LD50, mol/kg 
Fish Toxicity 0.9694 pLC50, mg/l 
Tetrahymena Pyriformis Toxicity -0.6339 pIGC50, ug/l 
 
Compound 8: Nonadecane 
 
ADMET predicted profile---Classification 
Model Result Probability 
Absorption 
Blood-Brain Barrier BBB+ 0.9821 
Human Intestinal Absorption HIA+ 0.9921 
Caco-2 Permeability Caco2+ 0.8284 
P-glycoprotein Substrate Non-substrate 0.6915 
P-glycoprotein Inhibitor Non-inhibitor 0.8985 
Non-inhibitor 0.7267 
Renal Organic Cation Transporter Non-inhibitor 0.8780 
Distribution 
Subcellular localization Lysosome 0.5981 
Metabolism 
CYP450 2C9 Substrate Non-substrate 0.8480 
CYP450 2D6 Substrate Non-substrate 0.7762 
CYP450 3A4 Substrate Non-substrate 0.7237 
CYP450 1A2 Inhibitor Non-inhibitor 0.6175 
CYP450 2C9 Inhibitor Non-inhibitor 0.9349 
CYP450 2D6 Inhibitor Non-inhibitor 0.9373 
CYP450 2C19 Inhibitor Non-inhibitor 0.9540 
CYP450 3A4 Inhibitor Non-inhibitor 0.9877 
CYP Inhibitory Promiscuity Low CYP Inhibitory Promiscuity 0.8149 
Excretion 
Toxicity 
Human Ether-a-go-go-Related Gene Inhibition Weak inhibitor 0.8620 
Non-inhibitor 0.8109 
AMES Toxicity Non AMES toxic 0.9965 
Carcinogens Carcinogens 0.6420 
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Model Result Probability 
Fish Toxicity High FHMT 0.9374 
Tetrahymena Pyriformis Toxicity High TPT 0.9947 
Honey Bee Toxicity High HBT 0.7485 
Biodegradation Ready biodegradable 0.7561 
Acute Oral Toxicity III 0.6143 
Carcinogenicity (Three-class) Non-required 0.6328 
ADMET predicted profile---Regression 
Model Value Unit 
Absorption 
Aqueous solubility -5.1776 LogS 





Rat Acute Toxicity 1.3444 LD50, mol/kg 
Fish Toxicity -0.7109 pLC50, mg/l 
Tetrahymena Pyriformis Toxicity 0.3450 pIGC50, ug/l 
 
Compound 9: 2,5-Furandione, dihydro-3-methylene 
 
ADMET predicted profile---Classification 
Model Result Probability 
Absorption 
Blood-Brain Barrier BBB+ 0.9627 
Human Intestinal Absorption HIA+ 0.9833 
Caco-2 Permeability Caco2+ 0.5452 
P-glycoprotein Substrate Non-substrate 0.7919 
P-glycoprotein Inhibitor Non-inhibitor 0.6266 
Non-inhibitor 0.9951 
Renal Organic Cation Transporter Non-inhibitor 0.8772 
Distribution 
Subcellular localization Mitochondria 0.6548 
Metabolism 
CYP450 2C9 Substrate Non-substrate 0.8815 
CYP450 2D6 Substrate Non-substrate 0.8935 
CYP450 3A4 Substrate Non-substrate 0.7178 
CYP450 1A2 Inhibitor Non-inhibitor 0.8434 
CYP450 2C9 Inhibitor Non-inhibitor 0.9264 
CYP450 2D6 Inhibitor Non-inhibitor 0.9524 
CYP450 2C19 Inhibitor Non-inhibitor 0.8061 
CYP450 3A4 Inhibitor Non-inhibitor 0.9487 
CYP Inhibitory Promiscuity Low CYP Inhibitory Promiscuity 0.9099 
Excretion 
Toxicity 
Human Ether-a-go-go-Related Gene Inhibition Weak inhibitor 0.9172 
Non-inhibitor 0.9875 
AMES Toxicity Non AMES toxic 0.8025 
Carcinogens Non-carcinogens 0.8480 
Fish Toxicity High FHMT 0.9233 
Tetrahymena Pyriformis Toxicity Low TPT 0.7182 
Honey Bee Toxicity High HBT 0.8293 
Biodegradation Ready biodegradable 0.7452 
Acute Oral Toxicity III 0.7565 
Carcinogenicity (Three-class) Non-required 0.5918 
ADMET predicted profile---Regression 
Model Value Unit 
Absorption 
Aqueous solubility -0.6464 LogS 
Caco-2 Permeability 0.9549 LogPapp, cm/s 
Distribution 
Metabolism 
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Model Value Unit 
Excretion 
Toxicity 
Rat Acute Toxicity 1.9632 LD50, mol/kg 
Fish Toxicity -0.0057 pLC50, mg/l 
Tetrahymena Pyriformis Toxicity -0.4252 pIGC50, ug/l 
 
Previous study showed that phytochemical constituents of B. ciliata 
are gallic acid, bergenin, (+)-afzelechin [26], 11-O-galloyl bergenin 
[27], paashaanolactone [26], β-Sitosterol [28] and β-Sitosterol-D-
glucoside [29]. Pharmacological properties have demonstrated that 
the root is well known in traditional medicine for protection against 
diarrhea; cough, in uric acid diathesis and in pulmonary infections 
[28]; coughs and colds, hemorrhoids, asthma and urinary problems 
[30]. The juice of B. ciliata leaves is used as drops to relieve earaches 
[30]. Currently, Various Ayurvedic classical drugs such as 
Pashanabhedadi kwath, Pashanabhedadi ghrit, Pashanabhedadi 
Churan etc. are prepared from Pashanbhed rhizome.  
CONCLUSION 
We have extracted, purified flavonoids by the liquid-liquid extraction 
method. Finally, ethyl acetate fractions were collected and 
characterized by GC-MS analysis. These fractions are used to perform 
glycolate oxidase and lactate dehydrogenase inhibition study. 
Flavonoids fraction of B. ciliata showed good enzyme inhibitory 
activity and ADME profile. Lineviewer-Burk plot and mode of 
inhibition confirmed the potential of it’s as glycolate oxidase and 
lactate dehydrogenase inhibitors. However, further dose adjustment 
and molecular mechanism study need to perform for better 
understanding. 
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